Clinical Trials Logo

Advanced Malignant Tumors clinical trials

View clinical trials related to Advanced Malignant Tumors.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06223841 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Start date: March 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

NCT ID: NCT06167486 Recruiting - Clinical trials for Advanced Malignant Tumors

SG2918 For Advanced Malignant Tumors

Start date: December 26, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.

NCT ID: NCT05991583 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Start date: June 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.

NCT ID: NCT05877924 Recruiting - Clinical trials for Advanced Malignant Tumors

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.

NCT ID: NCT05868876 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Start date: June 29, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ia/Ib open label,clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors

NCT ID: NCT05779163 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

NCT ID: NCT05396391 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Start date: June 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

NCT ID: NCT05354076 Recruiting - Clinical trials for Advanced Malignant Tumors

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Start date: March 1, 2000
Phase: Phase 2
Study type: Interventional

To study the correlation between the content of natural IgM in patients' blood samples and liposomal doxorubicin for clinical use, and to explore the possibility of using natural IgM content to guide clinical accurate medication.

NCT ID: NCT05235542 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Start date: July 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors

NCT ID: NCT05229497 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Start date: May 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors